KR102150027B1 - 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이 - Google Patents

종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이 Download PDF

Info

Publication number
KR102150027B1
KR102150027B1 KR1020197025813A KR20197025813A KR102150027B1 KR 102150027 B1 KR102150027 B1 KR 102150027B1 KR 1020197025813 A KR1020197025813 A KR 1020197025813A KR 20197025813 A KR20197025813 A KR 20197025813A KR 102150027 B1 KR102150027 B1 KR 102150027B1
Authority
KR
South Korea
Prior art keywords
expression
cells
pea3
deletion
recombinant adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197025813A
Other languages
English (en)
Korean (ko)
Other versions
KR20190104643A (ko
Inventor
토니 레이드
파라 헤드란
샨타누 쿠말
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20190104643A publication Critical patent/KR20190104643A/ko
Application granted granted Critical
Publication of KR102150027B1 publication Critical patent/KR102150027B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020197025813A 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이 Active KR102150027B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15682209P 2009-03-02 2009-03-02
US61/156,822 2009-03-02
PCT/US2010/025926 WO2010101921A2 (en) 2009-03-02 2010-03-02 Tumor-selective e1a and e1b mutants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012031A Division KR102020018B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이

Publications (2)

Publication Number Publication Date
KR20190104643A KR20190104643A (ko) 2019-09-10
KR102150027B1 true KR102150027B1 (ko) 2020-10-26

Family

ID=42710189

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197025813A Active KR102150027B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
KR1020187012031A Active KR102020018B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
KR1020117022884A Active KR101752910B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
KR1020177017391A Active KR101922539B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187012031A Active KR102020018B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
KR1020117022884A Active KR101752910B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
KR1020177017391A Active KR101922539B1 (ko) 2009-03-02 2010-03-02 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이

Country Status (15)

Country Link
US (6) US9073980B2 (https=)
EP (4) EP4123030A1 (https=)
JP (5) JP6072414B2 (https=)
KR (4) KR102150027B1 (https=)
CY (1) CY1122385T1 (https=)
DK (2) DK2403951T3 (https=)
ES (2) ES2750305T3 (https=)
HR (2) HRP20151396T1 (https=)
HU (2) HUE026386T2 (https=)
LT (1) LT3029144T (https=)
PL (2) PL3029144T3 (https=)
PT (2) PT2403951E (https=)
SI (2) SI3029144T1 (https=)
SM (2) SMT201900565T1 (https=)
WO (1) WO2010101921A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026386T2 (en) 2009-03-02 2016-06-28 Univ California Tumor-selective adenovirus e1a and e1b mutants
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
US10508303B2 (en) 2013-07-19 2019-12-17 Ludwig Institute For Cancer Research Ltd Whole-genome and targeted haplotype reconstruction
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
BR112019005964A2 (pt) * 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
EP3573632B1 (en) * 2017-01-30 2024-08-07 EpicentRx, Inc. Tumor selective tata-box and caat-box mutant oncolytic viruses
CA3052090A1 (en) * 2017-01-30 2018-08-02 Epicentrx, Inc. Multiple transgene recombinant adenovirus
JP7229173B2 (ja) * 2017-04-10 2023-02-27 エピセントアールエックス，インコーポレイテッド 組み換えウイルスを産生するための方法
EA201990822A1 (ru) * 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
US20200155625A1 (en) * 2017-05-24 2020-05-21 Epicentrx, Inc. Anti-angiogenic adenovirus
JP7216668B2 (ja) 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
WO2020046130A1 (en) * 2018-08-31 2020-03-05 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof
CN118931897B (zh) * 2024-06-27 2026-01-16 中山大学 一种识别肿瘤细胞并诱导其焦亡的基因、重组载体和重组病毒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
US20060270016A1 (en) 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643567A (en) 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5902925A (en) 1996-07-01 1999-05-11 Integrated Sensor Solutions System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
ES2325303T3 (es) * 1999-01-28 2009-09-01 Onyx Pharmaceuticals, Inc. Vectores adenoviricos lanzadera con e1b suprimida.
AU2001257611A1 (en) * 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
AU2001285263A1 (en) * 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
CN1183250C (zh) 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
GB0117198D0 (en) * 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
JP2005532829A (ja) * 2002-07-18 2005-11-04 インヴィトロジェン コーポレーション 組換え部位を含むウイルスベクター
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
US20100137415A1 (en) 2007-04-20 2010-06-03 Takara Bio Inc. Vector for gene therapy
HUE026386T2 (en) 2009-03-02 2016-06-28 Univ California Tumor-selective adenovirus e1a and e1b mutants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
US20060270016A1 (en) 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER CELL. 2002, vol. 1, no. 4, pp. 325-337.

Also Published As

Publication number Publication date
US12195766B2 (en) 2025-01-14
KR20190104643A (ko) 2019-09-10
PL2403951T3 (pl) 2016-04-29
JP2022023074A (ja) 2022-02-07
HUE026386T2 (en) 2016-06-28
KR20170077278A (ko) 2017-07-05
PT2403951E (pt) 2016-01-29
HRP20151396T1 (hr) 2016-03-25
HUE046565T2 (hu) 2020-03-30
ES2750305T3 (es) 2020-03-25
SI3029144T1 (sl) 2019-11-29
JP2016028035A (ja) 2016-02-25
WO2010101921A2 (en) 2010-09-10
JP6817979B2 (ja) 2021-01-20
JP6072414B2 (ja) 2017-02-01
EP3029144B1 (en) 2019-07-10
KR20110122866A (ko) 2011-11-11
HRP20191808T1 (hr) 2019-12-27
KR101752910B1 (ko) 2017-06-30
US9073980B2 (en) 2015-07-07
US20160017294A1 (en) 2016-01-21
US20230272349A1 (en) 2023-08-31
SMT201500329B (it) 2016-02-25
JP2020078326A (ja) 2020-05-28
EP2403951B1 (en) 2015-09-30
LT3029144T (lt) 2019-10-25
JP6375273B2 (ja) 2018-08-15
US20250327037A1 (en) 2025-10-23
ES2557812T3 (es) 2016-01-28
KR20180049188A (ko) 2018-05-10
PT3029144T (pt) 2019-10-28
DK2403951T3 (en) 2016-01-11
US11618888B2 (en) 2023-04-04
EP2403951A4 (en) 2012-08-22
WO2010101921A3 (en) 2011-01-06
PL3029144T3 (pl) 2020-06-01
EP2403951A2 (en) 2012-01-11
JP7326396B2 (ja) 2023-08-15
KR101922539B1 (ko) 2018-11-27
US10876097B2 (en) 2020-12-29
US20210171917A1 (en) 2021-06-10
JP2018113971A (ja) 2018-07-26
SMT201900565T1 (it) 2019-11-13
DK3029144T3 (da) 2019-10-21
EP3591059B1 (en) 2022-07-20
KR102020018B1 (ko) 2019-09-09
US20110318311A1 (en) 2011-12-29
US20190136204A1 (en) 2019-05-09
SI2403951T1 (sl) 2016-04-29
CY1122385T1 (el) 2021-01-27
EP3029144A1 (en) 2016-06-08
EP3591059A1 (en) 2020-01-08
EP4123030A1 (en) 2023-01-25
JP2012519014A (ja) 2012-08-23

Similar Documents

Publication Publication Date Title
JP7326396B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
CA2836987A1 (en) Chimeric adenoviruses for use in cancer treatment
JP4361708B2 (ja) 複製−コンピテント抗癌ベクター
US8951772B2 (en) Adenoviruses, nucleic acids coding therefor, and use thereof
WO2002053760A2 (en) Chimeric cytolytic viruses for cancer treatment
EP1558292A2 (en) Methods and vectors for controlling gene expression

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190902

Application number text: 1020187012031

Filing date: 20180426

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191002

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191021

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200526

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200825

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200825

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230810

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240806

Start annual number: 5

End annual number: 5